Recent QTRX transcripts
Associated QTRX filings
| Amol Chaubal | Chief Financial Officer |
| Kevin Hrusovsky | Chief Executive Officer |
| Puneet Souda | SVB Leerink |
| Sung Ji Nam | BTIG |
Ladies and gentlemen, thank you for standing by and welcome to the Quanterix Corporation Q4 2020 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to, Amol Chaubal, CFO of Quanterix. sir. ahead, go Please
Good me and Kevin on CEO. Chairman Charlie. us Hrusovsky, for today. and With today's afternoon, you, thanks everyone, joining our Thank call is
few would will and available statements Today's on section remind Before call be Resources be like Investor our begin, call will I you we about of things. the will Today's recorded forward-looking to website. contain actually call. as management's the not that assumptions available date and or on intentions statements. disclosed achieve information beliefs our of are We of expectations this based on and the forward-looking may plans, in
or and described risks, from and by may Commission. different with or in The statements. known are involve statements the the factors results, the filings to Securities other achievements assumptions any that future Forward-looking that forward-looking our performance implied actual we and unknown face expressed risks our uncertainties, results, materially and uncertainties Exchange recent performance be most cause achievements or
would not prepared over comparisons I With should our of financial These and financial financial accordance measures, you measure During that operations. reconciliations We non-GAAP with today's comparative not conference of in turn measures a website, considered of investors earnings to Principles with under the In substitute Kevin. U.S GAAP Accepted financial additional are presented accordance GAAP. with that release or to believe as GAAP regarding not measures. or disclosures these of a the measures. which measures on the available relevant measures non-GAAP provide are Accounting in call, our in find performance non-GAAP appendix call we QX our financial that, period-to-period Generally for will discuss will and measures these recognized some presentation, these in including isolation are be
we much, very do And you Amol. a pre-announcement. did Thank
think focus I will going oncology, the is we the Amol discuss through once But basically to And are dialogue ago. Alzheimer's, precision the go the higher-level QX we made coined a years our is proteomics phrase transform guiding go being the after our around creation ensure being in health, through deployed. really I primarily the a we'll numbers, become but in we strategy the this disruption about in advances will on we our go proteins charts, going six, important payer opportunity. that through presentation. to continue which in through COVID, with most So, value again actually the them powering just overall And way XXXX, is to way evolution think can in we revolution it's seven
on me pretty we Slide Let some advances. basically start significant made where X,
small to be think of of for whole level one of on differentiator measuring has of really of a each two to haulers that's go long at nasal after as with spots has the many enables nation the think effect, and us think able and we we particularly which as blood a measure battle unfortunately, quantitative years. the four a expect long help every company key that an anterior antibody, still swab are an COVID. giving which, measure world is the submitted we shortly And questions that several durability which also we test significant antigen submit in we've saliva. last semi for remain, dried trace and very with ability well about plagued us actual And and be employee for continuing vaccinations, One level think of hauler also having from months. it with many previous [ph] I had at COVID UAs us blood. Quanterix put individuals, in starts serology, to even pace the reached after the these out to amounts And the given to think the months probably pandemic XXX% antigen submitted enabled blood I us have and the antigen to the also is which in we
therapy this have well so will from And as of many with back Even of get COVID. key be taste lack health for to those trials and future as for that trying suffered just smell.
as well issues to but run will million, important as disrupt adoption. to created us a Radix, $XX out leading by think and of being group diagnostic utilizing phased be capabilities been And by neurological suspects of giving also are Group framework. has the and for strategic critical. FDA population will believe and haul longer-term to think and were healthcare we doing the with future to only this, be long The And COVID. also as been opportunities, going adoption, we million how trials COVID, or particularly, that created, ties a that for linked of linked NIH that We our lot expect granted as the menu we we many utilize in neurology we've subset UnitedHealth the allow to not work with to prevent has advances many researchers payer evolve figure we paired $XX
cohorts the of line through the our shown is presentation think this XX years across for being to this well pTau-XXX, and a On which neuro dementia. FDA. side getting drug see as for researchers as the bodies biomarkers as well, frontal [ph] dementia, Alzheimer Alzheimer right-hand disease we've evidence is Alzheimer's trials, From out temporal key lower important. differentiator before we us here, an disease to using stratify dementia, the of is with able the very accelerators, allows Also, drug
been continue are even COVID. had We early NFL our narrow those to amyloid peak to that evolve as never as important plexes also trials, drug [ph]. there more include than Plex beginning the now, of from neuro plan to want they and right to betas is Alzheimer Alzheimer's well who links house
side, term on be really to side once not on diagnostic a going drug a important but area is the longer growth our this think we is approved. ultimately for the So research only
you drugs continues our Abbott new later a continues. measuring Abbott publications can get one to into really of XXXX. had slowly is when their out higher Lab million Slide expansion advanced as the of earn sales came doing have The are $XX associated sensitivity are on you in on C a well see in as has lot versus older also of the royalty biomarkers. our our And NFL two also actually and the aging creating approved study plants trying we tracking well Record same new using end milestones, HDx and with payments of the put And technology. about upfront at that growth this are level did neuro And been level, XXXX. advanced biomarkers, we payments, The of we the to XXXx than by to major no double services were product introductions are a of now in really that license at just pilot a our lines past pace. dive XX% that growth January. private, as unprecedented lot fleet customers $XX as X outs, do another and And raise approved our a XXXX that level profile the inside our are our evolves now quantitation. We a investors million in when MS pace NFL of biopharma in drugs correlation year. also suites as
portfolio that it's get So both to companies drugs our at their approved for investors well are as a their that real being on helping win-win have as growth creator. as value focused
almost to that XX% to gone And to period to we very growth did we XX% of really research years. three comfortable XXXX. Our is the last over feel XX% XXXX growth state
year, the think consumer customer was projections being a key, what given QX almost we set landscape, and down. were for I And is at year. installed with as those very recovery this have we this for instruments look originally we increase key growth revenue, twice clip. in we many so of in think see we also be. our really XXX growth, this XX And HD thought our you labs also HDx's, And our rates XX% in accelerator utilization our last to important strong very to out is
to is drug showing of of growth And drug the rate slowest the in see. Quest Manager, we on mostly we medicine. approved you into growth recovering continuing period been strong years in is the then to to on expand the our our I just you usage them labs call consumables gives now XXXX great key which world, see got of we can you for on to TAMs a from strong a has the drug, technology we five-year this our samples. be have the for growth growth pace. well a are continue protein appreciation past CRO is Asia been revolutionize call valuation instruments excited trials services middle. continues We be also instruments, will that On over and very of see put $XX really continue because do right [ph] with the months, as molecules we the consumables did some a left-hand consumable gross new biomarkers. a through strong think given academics drug balance through $XXX strong balance where strongest opportunity inside think of inning hired evolution that side most we of CAGR we've [ph] homecare see base. less particularly put General growth clearly menu five currently sheet, growth, XXX there's neurology, And good This And X what low really, with and ability not achievement growth to reviewed what discovery, And with rescue an that to bringing is this even important and of risk growth, creating can strengthen growth of lot goes the future validate to lot And a because And very with with really these basically the these really strong I'm that starting see own slide will sensitivity, many across be others pretty as million shows is really revenue position. XXXX, based expect that dilution the think to $X relationships that's Chairman QX that great great breakdown house opportunity creates upstream. consumables, many in it's lot risk. on but publications. drives did see X, of to our the think six-year for the doing area a just overall second million the Intel says as publications billion tried technologies. and strongest Labcorp, these proteomics our us year can grow continue our you of you think expansion past is billion, Slide be rules or running gives large strong on do red the them X, to the a we're this and from evolve. we'll left-hand the overall invasive And further going number portion significant accelerated XX important. the this be and entrants, our really very trials pipeline instruments, what we've that valuation represents which particularly the in given creation installed year. is TAM know, we important no XX% the And that's complimentary that the continue for just you new of is think continues period We're democratized and couldn't growth we the a from validation real to you lot next as our contract. margin in our companies back and the well 'XX, we great while our in see our just Asia real party of But growth. in think in creates from of of the strong proteomics biomarker frontage peer differentiates And a a then first and those very our valuation. But that very but lab pipeline, recovery demographics will So reopening in significant and And it see trials where around others good ultimately, sheet. you we to just I which focus the see coming catalyst, is biotech, entrants gone then right, over our the be low we're we've represents company. XXX and have we've one growth, by strategy Customers And a pipeline. samples, our to that a And it really our obviously, for evolution, which the a we without services. at relationships and in sign, on in we with XX% [ph] and with validating the us lot year third regulatory even our know, the Slide reimbursement devices, our the can that And Slide instruments got side cash and can technology QX get our a with we of had now upstream drugs that's helping validating to publications as and now know $XX of 'XX. think we is as the instrument
starting compared we're with from we really over years in way field be risk our couple depending the focus, on we that think low MS, companies Ultimately FDA a are what biopsy, happens continue to But manage right-hand Siemens opportunity. goal to other very got biopsies. greater, because low deal, and NIH their liquid and size think been next has the pharma COVID of typically about, us franchise, and landscape are liquid relationships with shot On site Radix IBD avid and categories. better response It's very trials. drug levels in levels neural are to Alzheimer's drug with partnering at got crowded and deal for a worried now to the markets, have reducing the Alzheimer's single for other never still oncology look and companies disease the market XXx and all on our but got We've LVT. the in where of neuro validation the side data and and significant we a and TAMs areas
for and we really relationships think from the the a creation this So but right. standpoint, particularly on right, leapfrog we've left where payer struck these is capitalizing value the the both opportunity
helping NIH really intervene bridge look more right. biomarkers. given As side the going to ultimately create of then investments from more disease by the think looking a of instead very a evolutionary I think story and beneficial symptoms, before now, to with having left early aspirational reinvent is different the chance the for very diagnostics it's our to for build us right-hand industry, outcome of is much kind these basically the And, I trying this an with and prevent therapeutically when detection diseases patient, to
when on You in know level strategy And are our part how XX Slide, XX. moving hasn't detection overall Slide the shown them Slide the into current the and when versus can today when you that think Abbott, And can less we the asymptomatic changed XXXX second of shows same on you protein there's big of protein brings proteins successfully lumen red, great the study times the And biomarkers. of still for landscape the given and one region. for you DNA on provide COVID. more XXX proteins you less neuro indicative Five we ultimately bring what's just also think to and are XX times proteins. sample under vitally $XX But the billion very of XX expand Siemens, is are we others this think billion very really TAM, the already really show, $XXX is invasive, and see measured utility, the we there phenotypic could have is identical important. It's XX revenue. invasive you areas attempted x What's landscape, being when sensitivity twin $XX are proteins. measuring been really does grows Protein we XXXX testing five in cancer years. see telling in for in on side billion that significantly we discovered. though even alone. is disease there versus you diagnostic a some proteins, one know and do probability to level. left playing And is they research get different cancer pretty the think today's side utility And Roche we some measuring that's these this up players But this the to And other up of and RNA, creating and have regime. having diabetes, is twin the the Slide the proteomic measuring be grows protein opportunity get And that current it. it's
know, brought has they you be to just ready now create, show was revolution and on evolved ultimate genomic the Grail computer the out Slide sequencing, of as this alumina able whole spun revolutionized back that technology and XX. So opportunity is Grail that landscape We we in. to the believe proteomics of then and industry
downstream times the in on so the the companies lot And the three genomic cap I those right. market landscape this sits a right, is on of overall current with think value
Illumina. move here. we Grail a lessons so there's think know that smart the move lot that of And we was And a by
have aluminate, founded of same founder Quantex. the We
some make of get that downstream, to lessons don't from lose value value. we're to so learn downstream that we try try lot sure And trying to a those and and
see XX, of does multiplexing base we're paradigm symptoms. for lesson the and sensitivity in just building monitoring we're And Alzheimer's. to progression to across subtypes is achieve. we're disease where molecule before now, there's disease greater to the single But as don't homecare enable prioritizing we're all biomarker specificity ourselves what Slide particularly is focus proteins awesome right tremendous of And be going you that measuring using neurology able for this an for disease, samples this new landscape So can create crowded. we see, think technology to And and areas. first is on and
sensitivity that others the side, many think and to of biopsies these our lot the and put have great see is more today but we Group, that are that we've but proteins relationships And also can But signed Slide we have disease on United where the into talked our and to getting on COVID, of earlier. symptoms. at see here's of further these on well by We're as So specs largest final through we're see we're you can we on very customers the into evolved we and can validate slide we crowded, pipeline brain the a can TAM trials on as the Alzheimer's, advance and investment primarily into liquid look pipeline help we just final with continue medicine TBI. companies field companies are right-hand and think with Roche as one it's right, opportunity. moving we that starts left, do before slide next focused COVID. quantec GSI further create think when opportunities But TAM's of trying you to But to can then you Abbott what are. do look brings were Cigna, you partners drug Aetna, hoping screens the side further our Health when Nautilus is and this that left-hand from MS Siemens where that heart and presence. $XX expand well. oncology like you the to here, the think XX, billion to evolving we by add grows direct about And into seeing that only the partnering new that a the slide this OSI as
TAM across EUA a then and So what post in we and starts today, with neurology and cut once COVID, pre $XX COVID about did with narrative [ph]. do that is build And we, billion research. oncology go
strategic mostly going it into COVID. billion does with create into know, a upstream You back moving diagnostics strategy a TAM, doing we're $XX of for Trojan then what research but neuro, horse is and
have the of evolve start side sensitivity to groups, our ultimately, allows of and think haul and we the XX be we phase protein many think [ph], years. in us with samples. evolve of side which immunology EUA now less really an from think to do next Now, long with validation discovery research can building downstream the then around we then years we these next two, the for then invasive are of ability further virus the We think where be we have now, of the answers this upstream we this will it's And to that those get the think oncology pair the blood, you'll further disruption really of COVID the on into see able entering. new out we TAM, most players pathology to bringing three
think like of we it's discovery So of our lesson the piece benefit TAM We story. a don't sample. feel the we from priority. longer-term will base that's But think actually
biomarker are So when Slide where right where approved That's into they like hey, that on those discovery leads these we by a drug XX, technology. in load show never being use probability drugs biomarker a approved. to have lock been with companies adoption will when focus of today, Alzheimer's our we and we increase why disease XXX% neurology
get area to key clinical number validity. across it's on the them line. goal two the demonstrated And So
this we're many we're year doing we've these has those NFL secondary XX is of where it's the a drugs XXX% with [ph]. It's is half venous using patients of the those XXXX getting actual before trials. submission bringing Takeda, required are that blood ago, many help what as initially symptoms well a can as to to drugs Novartis, you down Slide Lilly and or see it's to enhances endpoints over primary as like neurofilament using cross We then that here, Blackstone And That's blood informing XXX got that expensive. think they've new been and a know, biomarkers discovered. on and landscape of ability. different Biogen two approved And now that is then across for spinal the we get and of story diseases a to down that's and a approved of publications, getting home spinal continues all really those were tap once standing the But the for screens, evolve right Roche. or be shows up exclusively and spinal with with drugs these ultimately, transforms taps tests ability light research into the and using to cohort markers are patients key very pet all very into biomarkers, simola our this Slide to antibiotic and get in and XX and six think, just to spots shows lot cerebral important using even and with now our used painful, pairs, those You CSF and fluid, $X,XXX, approved where and being technologies. The left. COVID. therapies them testing sensitivity it demonstrate can to leads different the see locked hard the pairs UA patients $X,XXX what of those dry what key very world presentation [indiscernible] these getting And important very trials have Pfizer, the drug a image. in because today's further a
in feel very support chance our are customers we got and up to very Slide for in could the But pTau-XXX, through thought right cohorts here allow approvals. pathology Biogen we've could we Alzheimer's using neurological amyloid Europe disease new this, our and a where towards we you the locked this both is Lilly where blood this to someday driving not key it for more that's coming simple recruited. can publications ends it become test primarily a about to And to reveal of now from out, FDA was we to see able and we This we a with to research So with think us research neurologists with that really And pTau-XXX, a now XXX. the of advanced Alzheimer's be of only seen allowing areas. right, but correlations may allow and doing diagnostics. early, to But XXX. these create to importantly, excited key see the early out stratify XX close center be on play it's
XX while selling initially So a IBD. year across on gets And that just you know, this you that referenced LDP is. think call no And think XX, growth, sensitivity it of this into site approved, to looking matter and our technology the for is Health deploying categories. what story. COVID that's lot world We at this possible if then conferences an Precision first creates In really will to of [ph] at the I need evolving the approved. we because usage Slide single allowed piece opportunity. can that single diagnostic is Alzheimer our technology. all the are think and of we're drug or we're the they're is the have Pyrant summits site the once all where Once approved our see not, Slide drug do Summit disease allows we big other companies see And to customers a technology of like area see going the
because difficult contagious is before very know and symptoms You unlike system really the antigen. to most makes that of Corona it the immune other can any types virus to other see the responses that you really virus control
we're negatives created adaptive that immune system first times have on many of you your not and storm led an because where where next it's of curves, right you from of you've testing, valuable you the the a deaths asymptomatic the a sorry, vaccines. the and with and technologies, we I'm I be that cytokine to range, right, them and these when COVID is Musk when to we the back workers you at on false can is to key think led the Colts the these to all and pneumonia is particular across these systems. detection for which tops is system broader immune manage that's system immune has governor and the the see believe This for Élan students technology will one the compromised window. And Ohio. measuring innate The cytokines get particular And this entire detection positive measurement, to But to the screening work a even where can is today's very it able for the is seen immune see of This really is window categories. allows many you see important really that left what's IGG, Indianapolis which adaptive. slide, our look ultimately lot
stroke, assessments. drug now a not Now the approvals, long as we that Lilly And for Alzheimer's from sometimes can as issues, XX the of to will technologies the follow-on from running blood we through of our neurologists. as trial be therapies we've someday to well types publications to virus COVID, think full fact, and only is And are there's from as see antibodies the as linkage that of arm we And that And for looking got This but with and the And symptoms or well to virus, the the using and for virus if entire Slide that being symptoms hauler assess going see now to different of Glaxo Gilead; kinetic long issues, the blood this from haul is cardiac which in associated therapies able these allow it we haul we those well spectrum the see smell, of a know, and think a itself. a of key degeneration. neuro with important Alzheimer of with eradicate lot taste key remdesivir the three And you right the the at key the technology, and to those supporting COVID. NIH measurement for technology is that NFL, like think of kill. with know Alzheimer this even fog. think XX the we in help also approvals, us is studies. us the measure respiratory are trials. but this And brain long deployed early menu some biomarkers shows COVID loss in
Slide of groups, the and these from our of Milken, that see attend many to innovation from groups them ecosystem we what group Michael leader think be to and cancer, can very we groups, the use and most the unlike health bring with CROs, us each up, associated Leroy other. research and lethal respect is game and they collaborations to that precision of below for to us a stay thought So connectivity is time, Quanterix like to COVID. relationships basically various of process. to this the with to a their thinking. with how constituencies information where proteomics the some these to with quickly investors, levels And us going Slide interconnect the where the many precision allows the health top opportunity allow Hood's connecting tries bring hospital revolution constituencies areas, is is and suite into also advocacy allows it many advance by been it try are key going XX with to be hiring have this brain, guide dots. to of how whether uniquely to and all many to like you And have as allows C slide PPH into we market and Quanterix catalyze our the us ahead most to shows diseases down to even be. that show sensitivity. cure patients. XX to try degeneration driven. find the be senior whether really XX, allows company own some industry are us as And And actually all driven is see proteomic we that technology scientists, of us then of whether those the lot agencies. groups, key And a we're it get even well And that And to various be those critical all neuro on
the the an disruption, opportunity for COVID, C, would effective that rapidly move a symptoms seeing into now and there's approved deploy there's biomarkers illnesses to advantage could already to with membership biomarkers they large we membership patients could for end with surveillance of to large an their of therapy those think identify biomarker. finally, initially, drug the groups awesome like disease diabetes before to biomarkers three lead group. their ways paired And think to do that drugs MS, there's is that where so to with pair then therapies outcomes trials And an peer and create of where recruiting And serious groups approved. more them B breakthrough scale just I'll for get be give ultimately we then category think and can getting the the groups by that incredibly into some create better many in our which today the cancer, outcomes a trials, they very next try pancreatic we long-term better in
a Q&A. we'll going now for Thanks to and with financial So close what do I'm to our updates, turn out Amol is then over some lot.
QX going some be and Kevin. financial full to about performance. Slide We'll page to XX Thanks, XX. year referring our our details additional I'm provide webcast XXXX
million Awards. QX of XXXX of from GAAP Kevin RADx revenue million noted, included $XX.X and was As $X.X in revenue
revenue. versus by Service Excluding million in revenue license increase in prior from with increase instrument and with revenues revenue our $XX.X revenue items $X.X full connection XX%. services these QX, was non-GAAP a and and XX% XXXX agreement increased revenue by Consumables non-recurring included QX for year XX% QX, in million driven in year accelerator million a a XXXX XX% XX% by Abbott nonexclusive QX. our was $XX.X increased GAAP QX, million in revenue QX. $XX.X revenue and in across RADx QX increased Awards
$XX.X COVID-XX. our interruptions versus in million increase customer sites installations items, was accessing and year, a non-GAAP XXXX their for prior year XX% non-recurring these in Excluding challenges customers revenue despite operations to facing due full
accounting be recognized disclosure discussed, previously accounting RADx; an grants and IS approximately in payments for grant our to total service to driven services the support XX, revenue RADx Under will sustain which we government as to clinical services package for that XX% revenue. increase Accelerator research in Coming accelerator their expanded our trials. of and of Awards courier under capacity by XX $X XX% we work have as XXXX. This IS recognized As half was milestone in [ph] our government are our proactively assistance. customers resulted a increase revenue million half of expect we approximately revenue grant approximately RADx of in
$X will the that and with million expect in recognized We milestone contract value statement. for approximately and have these and them to carrying revenue of property loss no of remainder remaining as assets reduction in equipments a to the will purchase XXXX. profit will recorded $X approximately as revenue the grant associated a in be reimbursement grant million $X be of The million payments relate
providing previously we As are revenue stated, guidance. not
seen recently pre customer have to activity return COVID levels. We
of and Corona in to resulting an QX may such of customer non-GAAP consumables or virus gross Europe. spread customer was gross interruptions challenges, of However prior lockdowns margin in basis laboratories as certain versus year points. increase basis new XXX in margin in approximately dropping QX a sites strain XX.X% the accessing potential XX.X% US limitations force a due On new utilization
as future and mix as RADx high business Our our XX.X% period verses was providing operations. impact a comparison margin period thus margin acquisition GAAP gross believe non-cash for overall acquisition non-GAAP significant towards our [ph], margin of QX relating well On margin QX Oman gross our gross investors of the grant consumables, purchase impacted relevant and We our in margin a scale the have year as accounting our opportunity costs. expansion excellent basis, we favorably product to prior adjustments to was and excludes by RADx we gross our awards XXXX services, evolve of related of with reduced XX.X%. revenue our
primarily totaled Our GAAP RADx expenses our exclude non-recurring QX $XX associated million. in XXXX. And operating expenses with $XX.X operating million revenue total expenses non-GAAP grant which
million unrestricted capital and Overall, outstanding priorities during balance. on for $XX During we $XXX cash proceeds line or $XX.X with XXXX increased in will QX we XXXX received proactive I year timing expectations. our And QX payments shares million working X RADx Basic our of by year net period. progress with cash in average pleased Abbott, with milestone XXXX, in driven and result the approximately from We close performance million full QX total pass million, QX million weighted through strategic are committed $X.X raised back Kevin. a delivering measures. to offering. balance public our and EPS by to payments, made and XXXX remained With solid for QX XXXX, $XXX.X that
Amol. you, Thank
We will Q&A. for open up
Puneet of Your Instructions] the question SVB comes Souda from first line [Operator with Leerink.
Your line is now open.
Yes. the Kevin. questions. Hi, for Thanks taking
is very well it's mean, ways, you know, sensitive more proteins proteomics. into and and you technologies. more interest Obviously, here investment proteins something detection do on significant I is one proteomics obviously, there's in in of flowing first most [ph]. and The Synovia the early-stage with importantly,
understand into side know, signpost screening large and proteins trying in be continuum at panels targeted more more how So, the of to overall even positioned you into do for and you're is that of Quanterix diagnostics? the then number be Quanterix early-stage a continuum just for things, of should proteomics Where out the and where and looking research you sort we the to sit what as research, large positioned to of from, looking
with lot landscape have that that this of there's it. really understand even for belief, spent and time executed, than think they entering before Puneet all confidence been even XX investments we of of And lot given of us, more and one I on sometimes questions question, do, a where entrants making be their good and it's a interesting, of upstream, ones doing a all I investors execution I new lot Very with get our we've should these about they prowess. years about because studying are this a
out landscape like now retirement but people that ago, years former company driving in the I this. and the of are some know, very companies, from seven of of have you in we As came most XXX a execution experienced the
can trying these to proteins. basically able lowest And continuum sit, saying play is the but being of in these where discovery of them, so lot they're is of when is is the or, which we through see they entrants people And that discovery. see you're what is of we we know, there to the much in really they see we've been some them a when find been of there's is the misinformation health a them those, they're level very that many would level, see can the like, seeing lowest approached around the companies, And out a these and markers. of of concentration you're the magic these challenge upstream measured mass in around it. of and the of these can be invasive where And things say markers, healthy, that samples downstream And we very disease. lot to a you way what are can spec finding we've new what that the role at
less unbiased. And you'll think really be healthy, them that let's see biased it the what really, a low unbiased, of totally Because or protein And a I themselves patient actually their concentration call a an in as say, invasive not a makes is condition, great it biomarker to sample, extent, and won't a, many in which find is of example, sensitivity. able that but to some unbiased. against at a if are is them is, technology they're
it think discovery. house, important you trying bring of it to value of a our Let's when discovery good we we one at not now think or samples invasive And even in it an it protein breath a start it But be really for good to up. think be lot NFL really blood going see from where disease, then when non-invasive is, to are even you you or can the way you sample. we what are an That's lower. younger saliva, many can in are can that condensate. goes a population, right the now like is see you everyone CSF, say times in the I health youngest see in big areas to in understand really levels we there are it's to protein entering see if So, are for again, companies And the it once then see the that that to of even also see in utility
times order positives, you're they're much it's NIH, and understand So be discovery seeing say to very of there that and between virus. different able what the person that people, to to is, antibodies for sample. that was ultimately, greatness diversity able There's able COVID. virus there this the but complete the how getting have that continuum, vary learning cleaning unravel of Many be to diversity. you a people the so of another around opportunities. when of lot with use quantitative question antibodies, even personalized, negatives that and level actual different our that to We're to going the to a real much which you to base those within up to lesson same weeks customers and seems is sample sensitivity the neutralizing the grunt ultimately, in allow mystery sensitivity to most that they want just is quantitate of low the viruses see it what's is of well, particularly need the in from being and brings false into be abundance to And in very quantitate COVID have that false the dilution, getting around
and franchise, into many is subtypes, and amongst pTau. create peer key to is sit. the body we're allow franchise it is right to really studies at the think be you the And Alzheimer's. ultimately, the the approved, into drug samples, pTau So you know, looking approved. subtypes utility this competitors blood where a those samples, opportunity at fairly evidence now to getting to seen our people that's fairly uniquely play differentiate third Tau NFL is been And The dementia were used that ability. we this I those non-invasive and drugs invasive the that only uniquely, where and sit looking you we spots have have when And that that with really screen total nice lot has the of both up drugs we a that those really dry trials for the reviewed of opens party, validated get who there. validate evolving of now, where And to
puzzle. proteomics, flowing lot think really long we So the flowing pieces just investment. creation, end with scenario make now it's people with those you the could value money happy in or And a of it's because a some are a I into up this where important anyway, of of term will not sure that question, long-term to want there's be
neurology That's great. That's very helpful. Kevin, I want to briefly touch on the trials.
us here which confidence, You the neurology can level for of up. saw in XXXX, indication and ramped trials XXXX, as more still a the terms can given and and, broadly confidence you of data in the just base Alzheimer's XXXX. have further as on of uptick We other a Parkinson's trials pandemic trials throughout sclerosis trials, get more in in bit of, Neurology have Any and sort of potentially Alzheimer's know, year? result terms saw was of number you a that you your of, multiple growth in and provide impacted we in done what's involved well major and measure
to and in relative of approved field showing used in for efficacy. that and validate that you very to XXXX, XXXX to actually to confident trials feel drug conform drugs to of a in have FDA the quantitate, trial, be about order for biomarkers biomarker guidelines have validity and to drug embryonic to the clinical very needed our penetration that level the start a is the current We in because neurological penetration, drug embryonic
them, been we're biomarkers And that's And there, feel penetrated. prospective and fluid, AMS where where term biomarkers, they're and NFL, samples. where MS drugs. that and years. to cerebral there's we validate it downstream it's then with proving like we several to see spinal trials allowed deploy And Novartis and to harder companies at many those out approved prove them two trials don't imaging, a and XX Alzheimer's new and so tap like XX% retrospective no And and invasive area so utility. approved existing so and has trials, lot we've approved really spinal so that technologies, drugs companies for like the only out they But the times, phase for for at Alzheimer even because phase is drugs like into translate are why trials and is drugs that look an expensive that's like these more been three started. Roche longer previously
asymptomatically. date lesson really our want that of for as know that look lot the diagnostic And term to based screening be or of deployed, a where for concentrated samples, for no to in and the to when technology what health longer as get leading is at where payer some now to pre they a there's we their the to opposed trials leading start sample. enter utility that longer payer to run medicine with anybody, on unearthing for this are biomarkers being then symptoms as base going Lily, term, samples, that's to groups blood a a it's recruitment bridging allows great And see samples. what you almost able Alzheimer we they're have part really would and bring of our going up drug many But of deploying in Like for so up we're get see the if those this by group actually ultimately utilized the peer be enable data, generation membership patients utilizing not next trials. the group for one actually we CSF, be because consider to the the highly place trials. to so to And showcase we they're purposes opportunity long, someday saliva groups of Biogen edge more to customers approved these biomarkers edge capability trials, of there's the of to of largest payer the to we are drug to those just and teaming as
secondly, we So to first dementia I the upsurge drug we're is we removing see bodies cohort using And do And by imaging and a more for dementia, look technology removing enrich tremendous [indiscernible] the think biomarker our than we temporal those One be thing years two taps utilizing move for presentation And gets efficacious. see for it's the once And dementia for then early drug. capability when to the of the easier to downstream, for approved, into several on a that and Alzheimer's. before recruitment it patients triage spinal reasons. next technology. then trials. a and of or screen frontal help stratification efficiently the drug
question. could those thanks for a near-term If ask I details. Okay, more
seeing you XX% the XXXX growth pointed as of you're mean, easy well. I number XXXX, have CAGR XX% in great for you First all, as XXXX, here, But ramp comparables have But you you to research think thoughts to that's term, up. believe. no on to here I I drivers these out of a longer trials have
us that out? just pointed like CAGR expect XXXX, meaningfully versus higher you why we growth in shouldn't So tell that
say headwinds a create to anyone we think almost beginnings we're measure. the some going that's go on I back is starts to try COVID had think of we XX% for from you category represents creation tailwinds, side, all, I've our non-GAAP lot headwinds really and CAGR, was in we're it weeks very model of CAGR, lot and interest would that. dollars of COVID. diagnostics. against. short longer-term value And new new Well, analysts, to really think on CAGR than In on it than a raise comps the we're because company That's and I did more billion to term. the that, execute investors really the value because I something period CAGR risk. our buy XXXX get just don't, stock a the tailwinds all this that I to we you I less of But is to based investors than of the there's much not a the Because plenty Puneet, opportunity. of remove some look you was comfortable into do in the good first to justified manage in remove ago, rate And had trying higher going evolving term, criticize short that that any from think because got just we've throw And it in versus you we COVID. few CAGR, a diagnostic the trying XXXX lot the of at I feel again, of was we because to I the we that to will for XX-hour that our when think can beyond CAGR, And XX% narrative look greater it to we And XXXX, investors. that's that, I it as warned and a many gross than things or our we at this because to result, conceived in be XXXX a of the and I growth so wouldn't make of probably had a a because what tried time agree demand
we don't for comps create hard XXXX. So
It's those see five-year institutions. base. EUA [ph] the a the opportunity to which short COVID. research institutions we be don't and the we're play. long tailwinds we students those for going surge be with institutions, or going to installations more to for to see value diagnostics we what these into of is COVID reason screening people this of investor an these our That our stock. So that COVID, the of a give then where lived, really give sustainability research us doing It's to want to people want for don't into effective haul might get for pathway for That's
I'll Kevin. Thanks. That's back hop into Sure. queue. fair,
Nam comes question from the line BTIG. Sung Ji with next of Your
lines Your now.
going capabilities, multiplexing forward? my right but Hi, of view, kind of multiplexing lot it's know, players, in just greater some your fits as much discovery compared is thanks guess, the questions. sensitivity, proteomics Was Quanterix progress view for to you the your curious curious think for taking we thank and talked critical downstream as about about so in around you how of think about while sensitivity, the landscape. you guys as early kind multiplexing these the of about Kevin, what Quanterix into kind all overall maybe you should attaining I of a the terms capability, made color in of fits haven't obviously multiplexing No, in that is area, not have capabilities.
they're of know, this, new signatures, I multiplex protein like, been the lot very bring that there's companies capable. knowledge, shotgun multiplex will at, shear, of and this and were discovery, GN it's pathology to a broad-based kind for of on, the I rich, lot that capability. questions entrant, also look a on old lot new really not in of identify broad want very a entrants, a evolving you I'm symbolizes have example pathology mass but to of a to value utility search think identify the very the a is an interesting link of slide proteins. Perfect I a working that trying to quantitate, for biomarker diagnostics. want to trials, want then shotgun like future to really working you're the lesson samples. And, because on spec between particularly ultimately, in that's evidence be linkage of and think you it's base the of want you when and you things, be where to looking a see I into the of becomes sample, sensitivity drug able into The these different dilute to presentations, is really where recent And and able there's you at important. and And of phase disease that's
there to the to And different side so what of role and to you're have for where it's single but TAM are is there, Abbott, goes a used I'm where bigger have of upstream billion we nearly that on someday, the the who of probably gets slide the value get value That's multiplex, you see going but then down And Plex, look lot XXX at, I drug in be the today, TAM creation companies, it's and and of created. think the not it's going that stages for shows to be for as Siemens the XXX% Plex. much as to the three the proteins, ultimately have and of doing discovery, want pipeline. a TAMs the overall And is it as instance, going you used significant trials, pipeline, basically Roche, diagnostics. $XX revenue basically
So on mean you that can a for see TAN here, interest, lot you of value the protein can and of what a in you once Plex. lot I create single hone of
probably in be specificity Plex utility. that once the XX and for Plex Plex So zone, gives ability you a going and that need of the to panel than the get create get to into needed you But the it's this disease do specificity you is to lot you upfront. situation gives a utility maybe you more XX you gives
be and be Does of that to run dollars lower. value so again, tests in Plex Abbott will for I in. proteins is value lot their that Roche, are the the number number the of high single Plex. be And of incredible of sit XX, very are And that that volume where run, the few you'll Siemens demonstrated that think find there to greatest But ability going create of all Plex help? for testing of I think a will a that and lot have with
you fantastic Yes, it's the payer that. to for so super helpful. hear And Thank you that's much partnering guys with groups.
readout? data see there we curious, might of the might visibility timeline be able kind into are have specific to studies know, currently you of are where though, the underway that you Just when
can population now that getting to that want drugs then three it's lead up they're for the That payer groups collecting. informing see was with with different eventually, two, try well saw of I coat what could want But three, And can't Yes, and two from to have discovery, see what even haven't announcement moment, up And biomarker teaming opportunities by pharma get right showed that teaming we that that approved you'll surveillance it's utilizing some to the approved, are end, at the ones example I be I of themselves do. think And might a that to at up. can one, is think companies. the think really I the to more the IRB publish. on public I been for see lot and slide you as going ago of to running probably, disease as are with and them they're months introduced Group data their where think their a an this say pair that to But additional UnitedHealth they at you to level. up that teaming we them how of what to membership cohorts. pharma Lilly biomarkers be able about
called learning's really precision we then members, using them, outcomes incredibly they to all to groups pair I think, practicing will getting care, continue health, their their see you'll There's surveillance their there, readout the see continuing it So to where at lot invite where biomarker a now that's This involvement aligned IRB's. they I of to conference you longer trying And how opportunity an it that you'll you between the think of term, for summit a a that really that's that powering gets started. the they're to is of we from know, for but will state. their independent them. much and probably quarterly the with of hopefully publish invite get home level, when and probably do they're easy and call, some know, and makes kind with that's what and that be
might disease of it test. in then of Great, to applications there super helpful. research like you field me, the you and sensitivity look at COVID sounds are curious you a But antigen if high and going foresee able of capabilities for detect being potentially whole disrupt know, the And Obviously, on very for viral future, you largely could interesting of diagnostics insight how forward? pathogens look infectious using kind currently. antigen do field at at detecting such viruses that's the into have lastly, kind guys the just antigens diseases, you it clinical
COVID. are think potential field of that do differentiating I there some opportunities in diagnostics that
this to landscape. the we vaccines to part a lived and it are know COVID. be of And we overall given the because long measure, probably do We would trying as investors that mislead of it would out think it's of easy given though, treat we subtract don't the how revenue, in timing it the
and suffering haulers, are So And area we And symptoms, recovery of in do later, at would anyone have expect them of that's still there'll looking one would six that from don't be there's taste smell. tailwinds. months be focus. them still long call some neurodegeneration, people just people types is and that to of could of heart from being COVID lot be a stroke previously, sometimes those have seen the had of or attack system that evidence linked and critical fatigued that there's and CNS area longer-term we've immune innate issues a other that another function many
their measure they it's nasal might, traditional track, tracking. or respiratory they if in and looking vascular for of all tract, the patients blood, the in an And body or so I do where think virus the it that these ensure pharyngeal using eradicated nasal diagnostics, some from virus the at that have may virus swabs, the there'll the only opportunity left be to blood have systemic
think right So hit a asymptomatic, the when the it's we samples before get could before that there, I whole a of more think symptoms. play could you're virus run, do field contagious, there see when that's we to then period important think we right role symptoms there'll most XX-hour manage, because to the be in so if IRB I the option. And diagnostic
if two But at entry those Unfortunately, that again, are for an for those effect. cut another meeting off a based in those haul here looking on to 'XX. chance think research potential buy into tailwinds. there's a long to get I keynote X:XX. going will us appreciate there's I us tailwinds institutions to that free years give the have more X.X to going since investors questions. last But we Thank have much you today. So of like been opportunity us. those really over given keep you you If appreciate us on for and time let to write we be people any really other to and at got know, support in some areas, It's all you questions, know there's don't other one. the we to you want we out if feel public. this to that to the very to one And updating us would reach us your
gentlemen, and concludes conference this participating. call. Ladies today's for you Thank
disconnect. now may You
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.